Ypsomed announced today that Chinese regulatory authorities approved the a dual GCP/GLP-1 drug delivered using its auto-injector.
The Chinese National Medical Products Administration (NMPA) approved Maxdutide, a first-in-class dual glucagon (GCG)/glucagon-like peptide-1 (GLP-1) receptor agonist, developed by Innovent Biologics. It treats people with obesity through delivery with an YpsoMate 1.0 auto-injector variant.
YpsoMate, a user-friendly device, helps patients carry out injections at home with confidence and minimal training. The auto-injector enables people with chronic conditions to manage health more independently while easing pressure on healthcare services.
Ypsomed said in a news release that China represents the world’s second-largest population affected by overweight and obesity. The company cited an increasing demand for GLP-1 as a key factor behind the construction of its new manufacturing site in Changzhou. Once approved by Chinese authorities, the company plans for the site to supply volumes of auto-injectors for this therapy. Until then, it plans to deliver devices from its Swiss and German production plants.
According to Ypsomed, its Changzhou facility strengthens supply chain resilience, ensures faster delivery and reinforces proximity to Chinese customers.
The company said Innovent chose it as its device partner based on its reliable auto-injector platforms and scale-up expertise. They have worked together since 2019.
